The global Gene Cell Therapy CDMO market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Gene Cell Therapy CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Gene Cell Therapy CDMO market size and forecasts, in consumption value ($ Million), 2019-2030
Global Gene Cell Therapy CDMO market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Gene Cell Therapy CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Gene Cell Therapy CDMO market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gene Cell Therapy CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gene Cell Therapy CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Catalent, Lonza, Thermo Fisher, ACG Biologics, Charles River, Oxford Biomedica, Novartis, OBiO, GenScript, Pharmaron, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Gene Cell Therapy CDMO market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
Gene Cell Therapy CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Immune Cells
Stem Cell
Viral Vector
Plasmid DNA
麻豆原创 segment by Application
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Hospital
Others
麻豆原创 segment by players, this report covers
Catalent
Lonza
Thermo Fisher
ACG Biologics
Charles River
Oxford Biomedica
Novartis
OBiO
GenScript
Pharmaron
Porton
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Gene Cell Therapy CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gene Cell Therapy CDMO, with revenue, gross margin, and global market share of Gene Cell Therapy CDMO from 2019 to 2024.
Chapter 3, the Gene Cell Therapy CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Gene Cell Therapy CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Cell Therapy CDMO.
Chapter 13, to describe Gene Cell Therapy CDMO research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Gene Cell Therapy CDMO by Type
1.3.1 Overview: Global Gene Cell Therapy CDMO 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Gene Cell Therapy CDMO Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Immune Cells
1.3.4 Stem Cell
1.3.5 Viral Vector
1.3.6 Plasmid DNA
1.4 Global Gene Cell Therapy CDMO 麻豆原创 by Application
1.4.1 Overview: Global Gene Cell Therapy CDMO 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Pharmaceutical and Biotechnology Companies
1.4.3 Research and Academic Institutions
1.4.4 Hospital
1.4.5 Others
1.5 Global Gene Cell Therapy CDMO 麻豆原创 Size & Forecast
1.6 Global Gene Cell Therapy CDMO 麻豆原创 Size and Forecast by Region
1.6.1 Global Gene Cell Therapy CDMO 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Gene Cell Therapy CDMO 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Gene Cell Therapy CDMO 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Gene Cell Therapy CDMO 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Gene Cell Therapy CDMO 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Gene Cell Therapy CDMO 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Gene Cell Therapy CDMO 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Catalent
2.1.1 Catalent Details
2.1.2 Catalent Major Business
2.1.3 Catalent Gene Cell Therapy CDMO Product and Solutions
2.1.4 Catalent Gene Cell Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Catalent Recent Developments and Future Plans
2.2 Lonza
2.2.1 Lonza Details
2.2.2 Lonza Major Business
2.2.3 Lonza Gene Cell Therapy CDMO Product and Solutions
2.2.4 Lonza Gene Cell Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Lonza Recent Developments and Future Plans
2.3 Thermo Fisher
2.3.1 Thermo Fisher Details
2.3.2 Thermo Fisher Major Business
2.3.3 Thermo Fisher Gene Cell Therapy CDMO Product and Solutions
2.3.4 Thermo Fisher Gene Cell Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Thermo Fisher Recent Developments and Future Plans
2.4 ACG Biologics
2.4.1 ACG Biologics Details
2.4.2 ACG Biologics Major Business
2.4.3 ACG Biologics Gene Cell Therapy CDMO Product and Solutions
2.4.4 ACG Biologics Gene Cell Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 ACG Biologics Recent Developments and Future Plans
2.5 Charles River
2.5.1 Charles River Details
2.5.2 Charles River Major Business
2.5.3 Charles River Gene Cell Therapy CDMO Product and Solutions
2.5.4 Charles River Gene Cell Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Charles River Recent Developments and Future Plans
2.6 Oxford Biomedica
2.6.1 Oxford Biomedica Details
2.6.2 Oxford Biomedica Major Business
2.6.3 Oxford Biomedica Gene Cell Therapy CDMO Product and Solutions
2.6.4 Oxford Biomedica Gene Cell Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Oxford Biomedica Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Gene Cell Therapy CDMO Product and Solutions
2.7.4 Novartis Gene Cell Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Novartis Recent Developments and Future Plans
2.8 OBiO
2.8.1 OBiO Details
2.8.2 OBiO Major Business
2.8.3 OBiO Gene Cell Therapy CDMO Product and Solutions
2.8.4 OBiO Gene Cell Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 OBiO Recent Developments and Future Plans
2.9 GenScript
2.9.1 GenScript Details
2.9.2 GenScript Major Business
2.9.3 GenScript Gene Cell Therapy CDMO Product and Solutions
2.9.4 GenScript Gene Cell Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 GenScript Recent Developments and Future Plans
2.10 Pharmaron
2.10.1 Pharmaron Details
2.10.2 Pharmaron Major Business
2.10.3 Pharmaron Gene Cell Therapy CDMO Product and Solutions
2.10.4 Pharmaron Gene Cell Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Pharmaron Recent Developments and Future Plans
2.11 Porton
2.11.1 Porton Details
2.11.2 Porton Major Business
2.11.3 Porton Gene Cell Therapy CDMO Product and Solutions
2.11.4 Porton Gene Cell Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Porton Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Gene Cell Therapy CDMO Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Gene Cell Therapy CDMO by Company Revenue
3.2.2 Top 3 Gene Cell Therapy CDMO Players 麻豆原创 Share in 2023
3.2.3 Top 6 Gene Cell Therapy CDMO Players 麻豆原创 Share in 2023
3.3 Gene Cell Therapy CDMO 麻豆原创: Overall Company Footprint Analysis
3.3.1 Gene Cell Therapy CDMO 麻豆原创: Region Footprint
3.3.2 Gene Cell Therapy CDMO 麻豆原创: Company Product Type Footprint
3.3.3 Gene Cell Therapy CDMO 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Gene Cell Therapy CDMO Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Gene Cell Therapy CDMO 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Gene Cell Therapy CDMO Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Gene Cell Therapy CDMO 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Gene Cell Therapy CDMO Consumption Value by Type (2019-2030)
6.2 North America Gene Cell Therapy CDMO 麻豆原创 Size by Application (2019-2030)
6.3 North America Gene Cell Therapy CDMO 麻豆原创 Size by Country
6.3.1 North America Gene Cell Therapy CDMO Consumption Value by Country (2019-2030)
6.3.2 United States Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Gene Cell Therapy CDMO Consumption Value by Type (2019-2030)
7.2 Europe Gene Cell Therapy CDMO Consumption Value by Application (2019-2030)
7.3 Europe Gene Cell Therapy CDMO 麻豆原创 Size by Country
7.3.1 Europe Gene Cell Therapy CDMO Consumption Value by Country (2019-2030)
7.3.2 Germany Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Gene Cell Therapy CDMO Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Gene Cell Therapy CDMO Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Gene Cell Therapy CDMO 麻豆原创 Size by Region
8.3.1 Asia-Pacific Gene Cell Therapy CDMO Consumption Value by Region (2019-2030)
8.3.2 China Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Gene Cell Therapy CDMO Consumption Value by Type (2019-2030)
9.2 South America Gene Cell Therapy CDMO Consumption Value by Application (2019-2030)
9.3 South America Gene Cell Therapy CDMO 麻豆原创 Size by Country
9.3.1 South America Gene Cell Therapy CDMO Consumption Value by Country (2019-2030)
9.3.2 Brazil Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Gene Cell Therapy CDMO Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Gene Cell Therapy CDMO Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Gene Cell Therapy CDMO 麻豆原创 Size by Country
10.3.1 Middle East & Africa Gene Cell Therapy CDMO Consumption Value by Country (2019-2030)
10.3.2 Turkey Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Gene Cell Therapy CDMO 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Gene Cell Therapy CDMO 麻豆原创 Drivers
11.2 Gene Cell Therapy CDMO 麻豆原创 Restraints
11.3 Gene Cell Therapy CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Gene Cell Therapy CDMO Industry Chain
12.2 Gene Cell Therapy CDMO Upstream Analysis
12.3 Gene Cell Therapy CDMO Midstream Analysis
12.4 Gene Cell Therapy CDMO Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Catalent
Lonza
Thermo Fisher
ACG Biologics
Charles River
Oxford Biomedica
Novartis
OBiO
GenScript
Pharmaron
Porton
听
听
*If Applicable.